Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial

医学 化疗 射频消融术 胰腺癌 内科学 肿瘤科 放射科 癌症 烧蚀 叶黄素 联合化疗 放射治疗
作者
Leonard W. F. Seelen,Lilly J. H. Brada,Marieke S. Walma,Steffi J. E. Rombouts,Manon N.G.J.A. Braat,Thomas L. Bollen,Inne H.M. Borel Rinkes,Rutger C. G. Bruijnen,Olivier R. Busch,Geert A. Cirkel,Lois A. Daamen,Freek D. Daams,Ronald M. van Dam,Otto M. van Delden,Wouter J.M. Derksen,Sebastiaan Festen,Karin Groothuis,Jeroen Hagendoorn,Ignace H. J. T. de Hingh,Mathieu André D’Hondt
出处
期刊:JAMA network open [American Medical Association]
卷期号:9 (3): e263861-e263861 被引量:3
标识
DOI:10.1001/jamanetworkopen.2026.3861
摘要

Importance: The poor prognosis and limited treatment options in patients with locally advanced pancreatic cancer (LAPC) highlight the need for novel therapies to increase survival. Objective: To assess whether the addition of radiofrequency ablation (RFA) to chemotherapy improves survival when compared with chemotherapy only in patients with nonprogressive LAPC. Design, Setting, and Participants: This international randomized clinical trial was performed from April 7, 2015, through December 6, 2022, in patients with unresectable LAPC with at least stable disease after 2 months of induction chemotherapy. The predefined study protocol reported a follow-up period of 18 months. Data analysis was performed from February 1, 2024, through January 15, 2025. Intervention: Randomization to receive either RFA with chemotherapy or chemotherapy alone. Main Outcomes and Measures: Primary outcome was overall survival. Secondary outcomes included progression-free survival, adverse events, and quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and pancreatic cancer module. Results: Overall, 188 patients (median [IQR] age, 65 [57-70] years; 100 [53%] men) were randomized, 95 to RFA with chemotherapy and 93 to chemotherapy only. Before randomization, induction chemotherapy had consisted of modified FOLFIRINOX (fluorouracil, oxaliplatin, irinotecan, and leucovorin) in 81 patients (85%) and a gemcitabine-based regimen in 14 patients (15%) in the RFA group vs 80 patients (86%) and 13 patients (14%) in the chemotherapy group, respectively. After a median follow-up of 55 months, median overall survival from randomization was 12.1 months (95% CI, 9.9-14.3 months) in the RFA group vs 11.6 months (95% CI, 9.4-13.9 months) in the chemotherapy group (hazard ratio, 1.07; 95% CI, 0.80-1.45; P = .64). Median progression-free survival was 5.8 months (95% CI, 4.4-7.2 months) in the RFA group and 6.9 months (95% CI, 5.3-8.5 months) in the chemotherapy group (P = .47). Grade 3 or higher serious adverse events were reported more often in the RFA group: 26 patients (27%) vs 10 patients (11%) (P = .004). Mean changes from baseline of -14.6, -12.0, and -18.4 were observed for the Global Health Status quality-of-life scores at 1, 3, and 18 months, respectively, numerically exceeding the threshold of 10 points for clinical relevance. In the chemotherapy-only group, mean changes from baseline on the Global Health Status remained below the threshold for clinical relevance. Conclusions and Relevance: This randomized clinical trial of patients with LAPC after 2 months of multiagent chemotherapy found that local ablative therapy with RFA did not improve survival compared with chemotherapy only and adversely affected patient's quality of life. Trial Registration: ClinicalTrials.gov Identifier: NCT03690323.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
蓝意完成签到 ,获得积分20
1秒前
xy完成签到,获得积分20
1秒前
wu完成签到,获得积分10
1秒前
2秒前
zkylh的应助被汪琪琪儿采纳,获得10
3秒前
土豆完成签到,获得积分10
3秒前
既白发布了新的文献求助10
4秒前
爱上人家四月完成签到,获得积分10
4秒前
魏伯璋发布了新的文献求助10
4秒前
4秒前
4秒前
HapenLIAO发布了新的文献求助20
4秒前
Mxz完成签到,获得积分10
5秒前
5秒前
xy发布了新的文献求助15
5秒前
要减肥的书蕾完成签到,获得积分10
6秒前
小赵爱漂亮完成签到 ,获得积分10
6秒前
知还完成签到 ,获得积分10
6秒前
6秒前
嚣张贤王完成签到,获得积分10
6秒前
FashionBoy的应助被北北采纳,获得10
6秒前
7秒前
苏鸣雅发布了新的文献求助10
7秒前
UN完成签到,获得积分10
8秒前
8秒前
10秒前
10秒前
久某发布了新的文献求助10
10秒前
嘟噜发布了新的文献求助10
11秒前
11秒前
不想上班发布了新的文献求助10
11秒前
王饱饱发布了新的文献求助10
12秒前
12秒前
jie发布了新的文献求助10
12秒前
上官若男的应助被机灵天宇采纳,获得10
12秒前
淳于易形完成签到,获得积分10
12秒前
kento发布了新的文献求助10
12秒前
Echo发布了新的文献求助10
12秒前
molihuakai的应助被酷酷柚子采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259